biotech news today obesity drugs glp-1 The race may have a new contender. π Regeneron reported Phase 3 data showing its drug candidate delivered up to 19.3% weight loss at 48 weeks, approaching the efficacy seen Stat News reporting Eli Lilly
Description
The risk-benefit calculation for semaglutide remains favorable for most patients with obesity or type 2 diabetes, conditions that carry their own serious long-term health risks
The judge has not yet made a decision on Eli Lillys request to dismiss the lawsuits or keep the plaintiffs experts out of trial
[DOI] [PMC free article] [PubMed] [Google Scholar] 148
Alcohol, at the same time, can lower your blood sugar and upset your stomach
He explained that weight gain causes irregular menstruation a common issue in PCOS and therefore, it can lead to reduced reproductive ability
